{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:02:19Z","timestamp":1790787739511,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40265-021-01504-2","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T07:02:52Z","timestamp":1617346972000},"page":"857-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Umbralisib: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"issue":"1","key":"1504_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26.","journal-title":"Mol Cancer."},{"issue":"1","key":"1504_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2013.087171","volume":"99","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Ottmann OG, Deininger M, et al. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica. 2014;99(1):7\u201318.","journal-title":"Haematologica"},{"key":"1504_CR3","unstructured":"US FDA. FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma [media release]. 5 Feb 2021. https:\/\/www.fda.gov\/."},{"key":"1504_CR4","unstructured":"TG Therapeutics. UKONIQ\u2122 (umbralisib): US prescribing information. 2021. https:\/\/www.tgtherapeutics.com\/. Accessed 23 Feb 2021."},{"key":"1504_CR5","unstructured":"TG Therapeutics. TG Therapeutics and Rhizen Pharmaceuticals announce global agreement for development and commercialization of novel PI3K Delta selective inhibitor, TGR-1202 [media release]. 16 Aug 2012. https:\/\/ir.tgtherapeutics.com\/."},{"key":"1504_CR6","unstructured":"TG Therapeutics. TG Therapeutics announces exercise of license option for its novel, next generation PI3K-Delta inhibitor, TGR-1202 [media release]. 23 Sep 2014. https:\/\/ir.tgtherapeutics.com\/"},{"key":"1504_CR7","unstructured":"Rhizen Pharmaceuticals. Rhizen Pharmaceuticals announces out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor [media release]. 23 Sep 2014. http:\/\/www.rhizen.com."},{"issue":"22","key":"1504_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood.V128.22.291.291","volume":"128","author":"C Deng","year":"2016","unstructured":"Deng C, Lipstein M, Scotto L, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3K Delta and CK1 epsilon in hematological malignancies [abstract]. Blood. 2016;128(22):291.","journal-title":"Blood"},{"issue":"4","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","volume":"19","author":"HA Burris 3rd","year":"2018","unstructured":"Burris HA 3rd, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19(4):486\u201396.","journal-title":"Lancet Oncol."},{"issue":"13","key":"1504_CR10","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","volume":"4","author":"K Maharaj","year":"2020","unstructured":"Maharaj K, Powers JJ, Achille A, et al. The dual PI3K\u03b4\/CK1\u03b5 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020;4(13):3072\u201384.","journal-title":"Blood Adv."},{"issue":"12","key":"1504_CR11","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/leu.2016.224","volume":"30","author":"SL Locatelli","year":"2016","unstructured":"Locatelli SL, Careddu G, Inghirami G, et al. The novel PI3K-\u03b4 inhibitor TGR-1202 enhances brentuximab vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia. 2016;30(12):2402\u20135.","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/hon.193_2631","volume":"37","author":"I Pal","year":"2019","unstructured":"Pal I, Sardinha AG, Scotto L, et al. Umbralisib and carfilzomib potently inhibit cap dependent translation in lymphoma [abstract no. 483]. Hematol Oncol. 2019;37(Suppl 2):510\u20131.","journal-title":"Hematol Oncol."},{"key":"1504_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03433","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.20.03433.","journal-title":"J Clin Oncol."},{"key":"1504_CR14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007376","author":"AR Mato","year":"2020","unstructured":"Mato AR, Ghosh N, Schuster SJ, et al. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K\u03b4 inhibitor therapy. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2020007376.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1504_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-134783","volume":"136","author":"JG Gribben","year":"2020","unstructured":"Gribben JG, Jurczak W, Jacobs R, et al. Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment naive (TN) and relapsed\/ refractory (R\/R) chronic lymphocytic leukemia (CLL): results from the phase 3 Unity-CLL study [abstract no. 543 plus oral presentation]. Blood. 2020;136(Suppl 1):37\u20139.","journal-title":"Blood"},{"issue":"1","key":"1504_CR16","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","volume":"6","author":"MS Davids","year":"2019","unstructured":"Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1\u20131b study. Lancet Haematol. 2019;6(1):e38\u201347.","journal-title":"Lancet Haematol."},{"issue":"21","key":"1504_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood.2019002118","volume":"134","author":"M Lunning","year":"2019","unstructured":"Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019;134(21):1811\u201320.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1504_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/hon.204_2631","volume":"37","author":"M Lunning","year":"2019","unstructured":"Lunning M, Bierman P, Bociek R, et al. A phase IIa study evaluating the safety and tolerability of umbralisib and ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma [abstract no. 494]. Hematol Oncol. 2019;37(Suppl 2):519.","journal-title":"Hematol Oncol."},{"issue":"22","key":"1504_CR19","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1182\/blood.V128.22.4146.4146","volume":"128","author":"R Ramchandren","year":"2016","unstructured":"Ramchandren R, Mulroney CM, Patel MR, et al. A phase I trial of TGR-1202, a next generation once-daily PI3Kdelta inhibitor, in combination with brentuximab vedotin, in patients with relapsed\/refractory Hodgkins lymphoma [abstract plus poster]. Blood. 2016;128(22):4146.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-134818","volume":"136","author":"PM Barr","year":"2020","unstructured":"Barr PM, Ma S, Zent CS, et al. A phase 1\/2 study of umbralisib, ublituximab, and venetoclax (U2-Ven) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract no. 3137 plus oral presentation]. Blood. 2020;136(Suppl. 1):41\u20132.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1504_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.79_2629","volume":"37","author":"AR Mato","year":"2019","unstructured":"Mato AR, Svoboda J, Luning Prak ET, et al. Phase I\/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with rel\/ref CLL and Richter\u2019s transformation [abstract no. 073 plus oral presentation]. Hematol Oncol. 2019;37(Suppl 2):119\u201320.","journal-title":"Hematol Oncol."},{"issue":"2","key":"1504_CR22","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","volume":"6","author":"LJ Nastoupil","year":"2019","unstructured":"Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019;6(2):e100\u20139.","journal-title":"Lancet Haematol."},{"key":"1504_CR23","unstructured":"TG Therapeutics. TG Therapeutics provides business update and reports fourth quarter and year-end 2020 financial results [media release]. 2 Mar 2021. https:\/\/ir.tgtherapeutics.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01504-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:11:30Z","timestamp":1620627090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01504-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01504-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"2 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon and Susan Keam are contracted\/salaried employees of Adis International Ltd\/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}